bursement and billing without knowing a lot about those processes. The information is entered by the clinical site that is providing the patient care and is then processed by Outcomes, which holds the contracts with the payers. Outcomes is basically the intermediary between the payers and the clinical pharmacist.
Kumbera: Outcomes is a national leader in the design, delivery, and administration of MTM programs. Even though the market is just waking up to MTM because of all the focus on Part D, we have been administering these types of programs with various payers since 1999. We work with employer groups, health plans, union funds, Medicaid, and, most recently, Medicare Part D programs. We have a national network of pharmacists who deliver MTM services face to face. Most of our pharmacists are in community pharmacies, but pharmacies associated with health systems in an outpatient setting are eligible to provide the services as well. That is how we are getting involved with Johns Hopkins, because it has outpatient pharmacies that serve the patients of MediCareFirst, which has outsourced its Part D MTM program to Outcomes.
Q: What specific MTM services can be reimbursed through Outcomes? A: Kumbera: We reimburse for a comprehensive medication review-a scheduled, face-to-face visit where the pharmacist and patient discuss prescription drugs, nonprescription drugs, herbal supplements, samples from the doctor, everything. The goal is to inventory all those drugs and look for cost-saving opportunities, drug therapy problems, drug-drug interactions, and other potential problems and resolve them by working with the patient and the prescriber. Brewer: When we complete the review, we may find that patients are taking medications very differently than their provider thinks they are. They could be taking more or less than what was prescribed. Another common discrepancy is when the patient never filled a prescribed medication, or perhaps has not filled it for a year. The physician may be unaware that the patient may also be taking herbal products. These discrepancies are picked up very quickly by the pharmacist in this comprehensive medication review.
Kumbera: We also pay for physician consultations. These may involve a pharmacist identifying a drug therapy problem-a dose too high, a dose too low, a drug-drug interaction, adverse effects, or a medication not working appropriately-and working with the physician to make a change to help that patient. Another covered service is patient compliance consultations between the patient and the pharmacist that do not necessarily involve the physician. For example, the pharmacist may see that a patient is overusing or underusing a medication, or perhaps the patient uses an inhaler and is consuming inhalers fast and wasting a lot of medication because of poor technique. The pharmacist can work with the patient to resolve that type of compliance problem.
The last area is patient education and monitoring. For any new or changed prescription, or if the pharmacist recommends a nonprescription product, we will pay to educate and monitor the patient. Education takes place before patients walk out the door, so they know what they should expect and how to use their medication properly. Telephone follow-up can determine if the medication is working and if the patient is still taking the drug properly or is having any problems. Personally, I believe that reimbursement models like these incentivize pharmacists to take more responsibility for the safety and the care of their patients. Even though pharmacists have been trained to provide patient-focused care, we do not routinely have time to spend 5 or 10 minutes with the patient talking about the control of diabetes, for example. By moving to one or more of these MTM systems, pharmacists can provide such care as part of the job. And that is important for the profession. I think this is the future of pharmacy.
Q:
At a more basic level, deciding to incorporate MTM services into pharmacy practice requires a needs assessment and an evaluation of the pharmacy and its workflow. Can the pharmacy staff continue to dispense products safely if the MTM program is added as a frontline function? Do the staff currently have the practical skills needed to perform MTM services? How many medication errors are occurring in the handoff between the hospital and the community pharmacies that could potentially be decreased through an outpatient MTM program? Q: How is Johns Hopkins implementing the MTM program? A: Brewer: We initiated this as a sixmonth pilot project starting in the Johns Hopkins outpatient pharmacies. We firmly believe that the majority of MTM services can be provided by any pharmacist.
My background as a primary caretrained pharmacist gave me a high level of comfort in dealing with the clinical situations that arise. Our biggest struggle is in bringing clinical services to a traditional community pharmacy model.
I am providing the initial clinical and administrative support for the MTM project. Our ultimate goal is to integrate financial and performance incentives to reward pharmacists for quality patient care. In April of this year, I started seeing Med-CareFirst patients and submitting MTM encounters to Outcomes.
So far, one other staff pharmacist at Johns Hopkins has become approved by Outcomes. Our plan is to expand this pilot to one or two pharmacists in each outpatient pharmacy. We are keeping it in a controlled environment so we can determine all the variables, identify implementation barriers, and make adjustments until the program is fully functional.
We are also evaluating how this program would work for frontline pharmacists-could they take a half day of each week for MTM, or would this just be worked into the day as needed? We are far from figuring out the optimal workflow for our site.
Throughout the pilot project, we are logging the number of hours we spend on MTM services and the number of patients we interview. We want to see how much reimbursement and time are needed per patient. We will also evaluate the type and importance of the interventions. Then we will decide whether we want to roll out the program to all of our patients or just focus on certain patient groups. So we are building the infrastructure for a full clinical pharmacist career track in outpatient health-system pharmacy. These patients may or may not know us and likely have never received full clinical services from their pharmacy when we first contact them. During the call, we only have 5-10 seconds to establish who we are and that we are from their local pharmacy. Next, we establish our competence and our empathy and describe the benefits we can offer that patient to enable the person to feel comfortable saying yes, I will sit down with you.
Q: How does Johns
Once they see you in person, most patients are a little more comfortable discussing their medications. That is a big lesson that we struggled with early on: You have to get the person in the chair.
There needs to be some sort of training to help pharmacists build the confidence that they can conduct sustained, 10-30-minute clinical interviews with patients. And that is what we are working on-building that confidence and expertise in our pharmacists so they can sit down and have these extended discussions and feel confident with their clinical skills.
It is also critical that there is a patient counseling area that is relatively secluded and relatively quiet, for confidentiality and to keep patients relaxed. You want them to be comfortable during the interview. At Johns Hopkins, we are using quiet conference rooms away from the pharmacy for the interviews. We meet patients in front of the pharmacy and walk them to the conference room.
Q: What part of the process has been unusually challenging for you? A: Brewer: MTM services are what I do in my private physician practice all day long, but my perspective is from that of the provider and prescriber. Trying to make MTM work from the pharmacy and dispensing viewpoint has actually been very challenging, because I do not have all of the information that I am used to having.
When I am in the clinic, I have laboratory and radiology results, acute care nurses, and the patient's physician right there in the same suite with me. I have all of the patient's medical history-the patient's chart is right in front of me.
But in the pharmacy with a MediCareFirst patient, I do not have all that information. So I cannot make as robust a recommendation about MTM services as I can at my other site. And, when I contact patients' physicians, they do not have the same relationship with me calling from the pharmacy that they would if I was working alongside them in their practice. These are all things that have to be taken into account as we are building our MTM program. One of the biggest positives about this system is the profession itself. We identify patients with drug-related problems, what we are trained to do, and communicate back to the health care team. The stronger our relationship with the provider, the more effective we will be. However, no permission is needed to provide our service. That is the future of pharmacy. Now, each hospital is going to have to sit down and look at its resources and look at its vision and mission and see if MTM aligns with them. The hospitals may or may not be ready for this, they may or may not be interested in this. But this, I believe, is where the profession is going. It is time to stop asking permission and time to step up and take care of our patients in the context of the entire health system. Kumbera: Pharmacists are the most logical providers of MTM services. If the profession does not step up to the plate and take advantage by strongly participating in the opportunities now available to pharmacists, others will do it, and we will lose that opportunity. If you like what you see at Outcomes, get your pharmacists trained, sign a Participating Agreement, and get paid for providing MTM services.
